在COVID-19及其大流行期间处理高脂血症:英国HEART专家小组的立场声明

2020-10-13 0 Atherosclerosis . 2020 Sep 15;313:126-136

导致2019年冠状病毒病(COVID-19)的新型严重急性呼吸综合症冠状病毒2(SARS-CoV-2)的出现导致大流行。 SARS-CoV-2具有高度传染性,其严重程度也具有很大差异。死亡率是无法预测

中文标题:

在COVID-19及其大流行期间处理高脂血症:英国HEART专家小组的立场声明

英文标题:

Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK

发布机构:

0

发布日期:

2020-10-13

简要介绍:

导致2019年冠状病毒病(COVID-19)的新型严重急性呼吸综合症冠状病毒2(SARS-CoV-2)的出现导致大流行。 SARS-CoV-2具有高度传染性,其严重程度也具有很大差异。死亡率是无法预测的,但会因一些因素而增加,包括年龄增长,动脉粥样硬化性心血管疾病,糖尿病,高血压和肥胖症。患有这些病症的患者中有很大一部分接受了降脂药物治疗,并且出现了有关在感染COVID-19的患者中继续降脂药物的安全性的问题。有些人建议他们可能会加剧病情。重要的是要考虑与降脂剂和针对COVID-19的特定疗法的已知相互作用。该声明旨在整理有关COVID-19患者降脂药物安全性的最新证据。我们根据当前的知识提出共识,并为这些建议评估了证据的强度和水平。我们使用以下搜索词广泛搜索了Pubmed,Google学者和Web of Science的文章,这些文章包括以下搜索词:SARS-CoV-2,COVID-19,冠状病毒,脂质,Statin,贝特类药物,依泽替米贝,PCSK9单克隆抗体,烟酸,胆汁酸螯合剂,营养品,红曲米,Omega-3-脂肪酸,洛米他肽,高胆固醇血症,血脂异常和Volanesorsen。当前没有证据表明降脂治疗在COVID-19感染的患者中是不安全的。不能因为大流行或COVID-19感染风险增加而中断降脂治疗。对于确诊为COVID-19的患者,应特别注意避免降脂药物与可用于治疗COVID-19的药物之间的药物相互作用,尤其是在肝功能检查异常的患者中。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=31b741c001991eec, title=在COVID-19及其大流行期间处理高脂血症:英国HEART专家小组的立场声明, enTitle=Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK, guiderFrom=Atherosclerosis . 2020 Sep 15;313:126-136, authorId=0, author=, summary=导致2019年冠状病毒病(COVID-19)的新型严重急性呼吸综合症冠状病毒2(SARS-CoV-2)的出现导致大流行。 SARS-CoV-2具有高度传染性,其严重程度也具有很大差异。死亡率是无法预测, cover=, journalId=0, articlesId=null, associationId=null, associationName=0, associationIntro=, copyright=0, guiderPublishedTime=Tue Oct 13 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>导致2019年冠状病毒病(COVID-19)的新型严重急性呼吸综合症冠状病毒2(SARS-CoV-2)的出现导致大流行。 SARS-CoV-2具有高度传染性,其严重程度也具有很大差异。死亡率是无法预测的,但会因一些因素而增加,包括年龄增长,动脉粥样硬化性心血管疾病,糖尿病,高血压和肥胖症。患有这些病症的患者中有很大一部分接受了降脂药物治疗,并且出现了有关在感染COVID-19的患者中继续降脂药物的安全性的问题。有些人建议他们可能会加剧病情。重要的是要考虑与降脂剂和针对COVID-19的特定疗法的已知相互作用。该声明旨在整理有关COVID-19患者降脂药物安全性的最新证据。我们根据当前的知识提出共识,并为这些建议评估了证据的强度和水平。我们使用以下搜索词广泛搜索了Pubmed,Google学者和Web of Science的文章,这些文章包括以下搜索词:SARS-CoV-2,COVID-19,冠状病毒,脂质,Statin,贝特类药物,依泽替米贝,PCSK9单克隆抗体,烟酸,胆汁酸螯合剂,营养品,红曲米,Omega-3-脂肪酸,洛米他肽,高胆固醇血症,血脂异常和Volanesorsen。当前没有证据表明降脂治疗在COVID-19感染的患者中是不安全的。不能因为大流行或COVID-19感染风险增加而中断降脂治疗。对于确诊为COVID-19的患者,应特别注意避免降脂药物与可用于治疗COVID-19的药物之间的药物相互作用,尤其是在肝功能检查异常的患者中。</p>, tagList=[], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8359, appHits=73, showAppHits=0, pcHits=347, showPcHits=8286, likes=2, shares=10, comments=8, approvalStatus=1, publishedTime=Mon Oct 19 18:02:43 CST 2020, publishedTimeString=2020-10-13, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Mon Oct 19 17:58:22 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 09:54:36 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=965944, encodeId=56bb965944d6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=601e2056901, createdName=1801ed04c5m, createdTime=Sat May 15 23:49:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895563, encodeId=f0aa895563f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83cb5430289, createdName=ms3000001410546383, createdTime=Fri Oct 30 04:46:28 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893088, encodeId=ad4989308862, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:15:07 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
    2021-05-15 1801ed04c5m

    很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=965944, encodeId=56bb965944d6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=601e2056901, createdName=1801ed04c5m, createdTime=Sat May 15 23:49:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895563, encodeId=f0aa895563f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83cb5430289, createdName=ms3000001410546383, createdTime=Fri Oct 30 04:46:28 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893088, encodeId=ad4989308862, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:15:07 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
    2020-10-30 ms3000001410546383

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=965944, encodeId=56bb965944d6, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=601e2056901, createdName=1801ed04c5m, createdTime=Sat May 15 23:49:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895563, encodeId=f0aa895563f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83cb5430289, createdName=ms3000001410546383, createdTime=Fri Oct 30 04:46:28 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893088, encodeId=ad4989308862, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:15:07 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
    2020-10-19 1244c0ebm28暂无昵称

    学习

    0